The 6 analysts offering 12-month price forecasts for NGM Biopharmaceuticals Inc have a median target of 5.00, with a high estimate of 9.00 and a low estimate of 4.00. The median estimate represents a -6.98% decrease from the last price of 5.38.
The current consensus among 6 polled investment analysts is to Hold stock in NGM Biopharmaceuticals Inc. This rating has held steady since October, when it was downgraded from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.52
Reporting Date Mar 01
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.